APGE — Apogee Therapeutics, Inc. stock price, charts and financials

Latest market price

134.65

-0.19-0.14%

Overview Short InterestFilings

APGEQT79Apogee Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

134.65-0.14%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PCVX+0.38%$58.29 ALKS+0.47%$49.40 IMVT-0.15%$39.89 IBRX-1.96%$7.49 RYTM-0.14%$115.47 KYMR+0.99%$108.58 CRNX+0.08%$84.15 SYRE+0.40%$105.33

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	17.31%	Shs Outstand	61.88M	Perf Week	0.56%

Market Cap	8.34B	Forward P/E	-	EPS next Y	-5.54	Insider Trans	-2.52%	Shs Float	57.17M	Perf Month	0.95%

Enterprise Value	7.90B	PEG	1.69	EPS next Q	-	Inst Own	-	Short Float	7.23%	Perf Quarter	64.82%

Income	-243.63M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	1.65	Perf Half Y	117.03%

Sales	0.00	P/B	7.48	EPS next Y	-24.72%	ROA	-21.23%	Short Interest	4.13M	Perf YTD	78.64%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-32.64%	52W High	134.69 -0.03%	Perf Year	271.26%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-24.15%	52W Low	34.29 292.66%	Perf 3Y	547.96%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	0.19% 0.21%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-31.21%	Oper. Margin	0.00%	ATR (14)	0.92	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	32.59	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	80.36	Recom	2.73

Dividend Gr. 3/5Y	-	Current Ratio	32.59	EPS Q/Q	-11.58%	SMA20	0.48%	Beta	0.98	Target Price	125.52

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	14.18%	Rel Volume	0.56	Prev Close	134.84

Employees	261	LT Debt/Eq	0.01	Earnings	Aug 10	SMA200	58.78%	Avg Volume	2.68M	Price	134.65

IPO Date	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.59% -	Net Debt/EBITDA	1.63	Volume	1,491,070	Change	-0.14%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-24-26	Reiterated	Stifel Nicolaus		$133 → $135
Jun-24-26	Downgrade	Stifel	Buy → Hold
Jun-24-26	Downgrade	TD Cowen	Buy → Hold
Jun-24-26	Downgrade	Guggenheim	Buy → Neutral
Jun-24-26	Downgrade	Mizuho	Outperform → Neutral	$135
Jun-23-26	Downgrade	Deutsche Bank	Buy → Hold	$135
Jun-23-26	Downgrade	Citigroup	Buy → Neutral
Jun-23-26	Reiterated	RBC Capital	Sector Perform	$97 → $135
Jun-23-26	Downgrade	UBS	Buy → Neutral	$135
Jun-23-26	Downgrade	Wedbush	Outperform → Neutral

Latest News

Aug-04-26

Aug-04-2609:25AM

'AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal' - BloombergBenzinga

Jul-31-26

Jul-31-2612:00PM

Are DSGR, AVB, SLP, APGE Obtaining Fair Deals for their Shareholders?gurufocus.com

Jul-30-26

Jul-30-2601:00PM

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGEgurufocus.com

Jul-28-26

Jul-28-2610:41AM

Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?zacks.com

Jul-24-26

Jul-24-2610:46AM

AbbVie: A Dividend Fortress At An Appealing Price TagSeekingAlpha

Jul-21-26

Jul-21-2606:30PM

3 Reasons to Buy AbbVie Stock Like There's No Tomorrowfool.com

Jul-13-26

Jul-13-2605:06PM

Big Pharma's $300 Billion Patent Problem Fuels Biotech Dealsetftrends.com

Jul-08-26

Jul-08-2602:00PM

Biotech Euphoria Driven By FundamentalsSeekingAlpha

Jul-06-26

Jul-06-2609:00PM

Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?gurufocus.com

Jul-02-26

Jul-02-2605:34AM

Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholdersglobenewswire.com

Jun-30-26

Jun-30-2603:45PM

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?fool.com

11:55AM

U.S. Equity Markets: Lots Of Gambling Going OnSeekingAlpha

Jun-29-26

Jun-29-2612:11PM

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highszacks.com

Jun-26-26

Jun-26-2601:52PM

Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic BankruptcyBenzinga

Jun-24-26

Jun-24-2610:59AM

Stifel Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135Benzinga

Company

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	0	0	0	—
Cost of Goods Sold Incl. D&A	1	0	0	—
Gross Profit	-1	0	0	—
Selling, General and Administrative Excl. Other	71	49	25	—
Research and Development	215	168	68	—
Other Operating Expense	-2	0	0	—
Operating Income	-286	-217	-93	—
Interest Expense	0	0	0	—
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	30	35	9	—
Net Income Before Taxes	-256	-182	-84	—
Income Taxes	0	0	0	—
Consolidated Net Income	-256	-182	-84	—
Net Income From Continuing Operations	-256	-182	-84	—
Net Income	-256	-182	-84	—
EPS (Recurring)	-4.22	-3.30	-1.66	—
EPS (Basic, Before Extraordinaries)	-4.22	-3.30	-1.66	—
EPS (Diluted)	-4.22	-3.30	-1.66	—
EBITDA	-254	-182	-75	—
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	—	—	—
Price To Sales Ratio	—	—	—	—
Gross Margin	—	—	—	—
Operating Margin	—	—	—	—
Net Margin	—	—	—	—
Shares Outstanding	61	55	51	—
Market Capitalization	4,604	2,492	1,425	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dambkowski Carl	Chief Medical Officer	Aug 05 '26	Sale	134.17	5,500	737,935	168,498	Aug 07
Dambkowski Carl	Chief Medical Officer	Aug 05 '26	Option Exercise	22.86	4,125	94,298	173,998	Aug 07
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jul 08 '26	Sale	133.63	20,000	2,672,600	995,987	Jul 10
Dambkowski Carl	Chief Medical Officer	Jul 01 '26	Option Exercise	22.86	4,125	94,298	183,373	Jul 02
Dambkowski Carl	Chief Medical Officer	Jul 01 '26	Sale	132.74	5,500	730,070	177,873	Jul 02
Dambkowski Carl	Chief Medical Officer	Jun 22 '26	Sale	132.60	26,400	3,500,640	179,248	Jun 24
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jun 22 '26	Sale	132.54	80,000	10,603,200	1,015,987	Jun 24
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jun 10 '26	Sale	83.38	20,000	1,667,621	1,095,987	Jun 12
Dambkowski Carl	Chief Medical Officer	Jun 03 '26	Sale	78.71	5,500	432,905	205,648	Jun 05
Dambkowski Carl	Chief Medical Officer	Jun 03 '26	Option Exercise	22.86	4,125	94,298	211,148	Jun 05
HENDERSON MICHAEL THOMAS	Chief Executive Officer	May 13 '26	Sale	82.09	20,000	1,641,711	1,115,987	May 15
Dambkowski Carl	Chief Medical Officer	May 06 '26	Option Exercise	22.86	4,125	94,298	212,523	May 08
Dambkowski Carl	Chief Medical Officer	May 06 '26	Sale	84.14	5,500	462,784	207,023	May 08
Henderson Jane	Chief Financial Officer	May 01 '26	Sale	82.04	2,000	164,080	173,371	May 04
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 16 '26	Option Exercise	22.86	3,000	68,580	1,135,987	Apr 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.